{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:03:54Z","timestamp":1768521834623,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish Ministry of Economy and Competitiveness","award":["BIO2014-5258P"],"award-info":[{"award-number":["BIO2014-5258P"]}]},{"name":"Gobierno de Arag\u00f3n\/Fondo Social Europeo"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.trsl.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T23:06:36Z","timestamp":1523055996000},"page":"32-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer"],"prefix":"10.1016","volume":"197","author":[{"given":"Samuel","family":"Alvarez-Arguedas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Uranga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Elizalde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Belen","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Juli\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Nardelli-Haefliger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nacho","family":"Aguilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2018.03.004_bib0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14737140.2017.1313119","article-title":"Tackling non-muscle invasive bladder cancer in the clinic","volume":"17","author":"Woldu","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.trsl.2018.03.004_bib0035","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette-Guerin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0040","first-page":"1762","article-title":"Intravesical bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Guerin","volume":"47","author":"Ratliff","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.004_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0050","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2018.03.004_bib0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14760584.2017.1324303","article-title":"MTBVAC from discovery to clinical trials in tuberculosis-endemic countries","volume":"16","author":"Marinova","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.trsl.2018.03.004_bib0060","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.trsl.2018.03.004_bib0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different bacillus Calmette-Guerin substrains","volume":"189","author":"Secanella-Fandos","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1265720","article-title":"Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer","volume":"6","author":"Domingos-Pereira","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trsl.2018.03.004_bib0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2018.03.004_bib0080","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1258\/002367705774286475","article-title":"Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy","volume":"39","author":"Loskog","year":"2005","journal-title":"Lab Anim"},{"key":"10.1016\/j.trsl.2018.03.004_bib0085","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.juro.2007.11.045","article-title":"The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study","volume":"179","author":"Pan","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0090","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-12-1882","article-title":"Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells","volume":"73","author":"Redelman-Sidi","year":"2013","journal-title":"Cancer Res"},{"issue":"pt 4","key":"10.1016\/j.trsl.2018.03.004_bib0095","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1242\/jcs.102.4.867","article-title":"M-CSF-induced macropinocytosis increases solute endocytosis but not receptor-mediated endocytosis in mouse macrophages","volume":"102","author":"Racoosin","year":"1992","journal-title":"J Cell Sci"},{"key":"10.1016\/j.trsl.2018.03.004_bib0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","article-title":"BCG immunotherapy for bladder cancer\u2014the effects of substrain differences","volume":"10","author":"Gan","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.trsl.2018.03.004_bib0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","article-title":"Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity","volume":"86","author":"Zhao","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.trsl.2018.03.004_bib0115","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1128\/iai.56.12.3046-3051.1988","article-title":"Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG","volume":"56","author":"Abou-Zeid","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.trsl.2018.03.004_bib0120","doi-asserted-by":"crossref","first-page":"35223","DOI":"10.1074\/jbc.M802660200","article-title":"Genetic toggling of alkaline phosphatase folding reveals signal peptides for all major modes of transport across the inner membrane of bacteria","volume":"283","author":"Marrichi","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.03.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004183","article-title":"The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in Mycobacterium tuberculosis","volume":"10","author":"Solans","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2018.03.004_bib0130","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1016\/j.vaccine.2014.07.113","article-title":"Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG)","volume":"32","author":"Copin","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2018.03.004_bib0135","doi-asserted-by":"crossref","first-page":"16085","DOI":"10.1038\/ncomms16085","article-title":"Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis","volume":"8","author":"Aguilo","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2018.03.004_bib0140","first-page":"1315","article-title":"Internalization of Mycobacterium bovis, bacillus Calmette Guerin, by bladder cancer cells is cytotoxic","volume":"18","author":"Pook","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.trsl.2018.03.004_bib0145","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kjms.2015.05.005","article-title":"Bacille Calmette-Guerin can induce cellular apoptosis of urothelial cancer directly through toll-like receptor 7 activation","volume":"31","author":"Yu","year":"2015","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.trsl.2018.03.004_bib0150","first-page":"397","article-title":"A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity","volume":"31","author":"Etna","year":"2014","journal-title":"ALTEX"},{"key":"10.1016\/j.trsl.2018.03.004_bib0155","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.trsl.2018.03.004_bib0160","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:05:02Z","timestamp":1658102702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524418300513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":31,"alternative-id":["S1931524418300513"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2018.03.004","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}